Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis ... plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and soles of the feet.

and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint. Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in ...

VYNE Therapeutics Inc. has announced that the FDA has placed a clinical hold on its Phase 1b study of VYN202 for moderate-to-severe plaque psoriasis due to observed testicular toxicity in dogs ...

The FDA slapped a clinical hold on a phase 1b plaque psoriasis trial after testicular toxicity was reported in dogs from a nonclinical test. Research into the use of BET inhibitors to treat cancer ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and insights that, taken together, suggest treatment strategies that offer the ...

Biologic treatment costs for plaque psoriasis more than doubled from 2007 to 2021, despite cheaper alternatives. Switching to the lowest-cost biologic in each class could reduce treatment costs by ...

China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque psoriasis in adults. An interleukin ...

Patanjali Ayurved's research, published in the Journal of Inflammation Research, reveals promising results for their Ayurvedic treatment of psoriasis using Psorogrit tablets and Divya Taila.

Ebdarokimab was evaluated in five clinical studies involving Chinese patients with moderate-to-severe plaque psoriasis. Two pivotal Phase III studies demonstrated ebdarokimab's efficacy and safety ...

Ebdarokimab was evaluated in five clinical studies involving Chinese patients with moderate-to-severe plaque psoriasis. Two pivotal Phase III studies demonstrated ebdarokimab's efficacy and safety at ...

"The approval of NDUVRA (tapinarof cream) introduces a new treatment option for adult patients with mild to severe plaque psoriasis. In clinical trials, patients who achieved complete disease ...